The Goldman Sachs Group Cuts Protagonist Therapeutics (NASDAQ:PTGX) Price Target to $38.00
Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) had its price objective cut by research analysts at The Goldman Sachs Group from $43.00 to $38.00 in a report released on Monday,Benzinga reports. The firm presently has a “neutral” rating on the stock. The Goldman Sachs Group’s price objective would suggest a potential upside of 8.29% from […]
Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) had its price objective cut by research analysts at The Goldman Sachs Group from $43.00 to $38.00 in a report released on Monday,Benzinga reports. The firm presently has a “neutral” rating on the stock. The Goldman Sachs Group’s price objective would suggest a potential upside of 8.29% from […]
